BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,140 filers reported holding BAXTER INTL INC in Q4 2021. The put-call ratio across all filers is 1.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $531,447 | -20.9% | 14,082 | -4.5% | 0.07% | -25.0% |
| Q2 2023 | $671,636 | +11.6% | 14,742 | -0.7% | 0.09% | +6.0% |
| Q1 2023 | $602,033 | +1.7% | 14,843 | +27.9% | 0.08% | -33.6% |
| Q4 2022 | $591,732 | +0.1% | 11,609 | +5.9% | 0.12% | -6.0% |
| Q3 2022 | $591,000 | -15.7% | 10,966 | +0.5% | 0.13% | -9.5% |
| Q2 2022 | $701,000 | -17.3% | 10,909 | -0.2% | 0.15% | -8.7% |
| Q1 2022 | $848,000 | -9.5% | 10,931 | +0.1% | 0.16% | -9.0% |
| Q4 2021 | $937,000 | +8.4% | 10,919 | +1.7% | 0.18% | -1.7% |
| Q3 2021 | $864,000 | +4.5% | 10,736 | +4.5% | 0.18% | +3.4% |
| Q2 2021 | $827,000 | -7.0% | 10,269 | -2.6% | 0.17% | -15.9% |
| Q1 2021 | $889,000 | +6.1% | 10,543 | +0.9% | 0.21% | +1.0% |
| Q4 2020 | $838,000 | -3.8% | 10,446 | -3.5% | 0.20% | -10.5% |
| Q3 2020 | $871,000 | -7.4% | 10,827 | -0.9% | 0.23% | -13.6% |
| Q2 2020 | $941,000 | +11.5% | 10,927 | +5.1% | 0.26% | -9.2% |
| Q1 2020 | $844,000 | -4.0% | 10,399 | -1.0% | 0.29% | +17.7% |
| Q4 2019 | $879,000 | -6.2% | 10,508 | -1.9% | 0.25% | -11.1% |
| Q3 2019 | $937,000 | +2.4% | 10,712 | -4.2% | 0.28% | +3.3% |
| Q2 2019 | $915,000 | – | 11,178 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |